Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

Jean Pierre Issa, Guillermo Garcia-Manero, Xuelin Huang, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Mark Brandt, Sherry Pierce, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Hypomethylating agents have demonstrated activity in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Preclinical and single-arm trials have suggested that adding histone deacetylase (HDAC) inhibitors may synergize the epigenetic modulation of hypomethylating agents and improve treatment results. METHODS: The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML. RESULTS: Patients with higher risk MDS or with AML aged ≥60 years were eligible. Patients were randomized in a Bayesian response-adaptive design to receive intravenous decitabine 20 mg/m2 daily for 5 days or decitabine plus oral valproic acid 50 mg/kg daily for 7 days. Courses were repeated every 4 to 6 weeks. A maximum of 150 patients were to be treated. In total, 149 patients were treated on study, including 87 patients with MDS and 62 patients with AML. The median patient age was 69 years (range, 20-89 years; 42% of patients were aged ≥70 years). Overall, 34% of patients achieved complete remission, and 55% had an objective response. The median survival was 11.9 months, and the estimated 2-year survival rate was 27%. Outcome was not different with the addition of valproic acid to decitabine versus decitabine alone in relation to the rates of complete remission, overall response, or survival. Subset analyses did not demonstrate a benefit within the MDS or AML categories. Toxicities - particularly neurotoxicities - were higher with the combination arm. CONCLUSIONS: Adding valproic acid to decitabine was not associated with improved outcome in the treatment of patients with MDS or elderly patients with AML. Future therapies may consider combining hypomethylating agents with better HDAC inhibitors and using different schedules.

Original languageEnglish (US)
Pages (from-to)556-561
Number of pages6
JournalCancer
Volume121
Issue number4
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

decitabine
Myelodysplastic Syndromes
Valproic Acid
Acute Myeloid Leukemia
Histone Deacetylase Inhibitors

Keywords

  • Acute myelogenous leukemia
  • Decitabine
  • Histone deacetylase
  • Hypomethylating agents
  • Inhibitors
  • Myelodysplastic syndrome
  • Trials
  • Valproic acid

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. / Issa, Jean Pierre; Garcia-Manero, Guillermo; Huang, Xuelin; Cortes, Jorge; Ravandi, Farhad; Jabbour, Elias; Borthakur, Gautam; Brandt, Mark; Pierce, Sherry; Kantarjian, Hagop M.

In: Cancer, Vol. 121, No. 4, 01.02.2015, p. 556-561.

Research output: Contribution to journalArticle

Issa, JP, Garcia-Manero, G, Huang, X, Cortes, J, Ravandi, F, Jabbour, E, Borthakur, G, Brandt, M, Pierce, S & Kantarjian, HM 2015, 'Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia', Cancer, vol. 121, no. 4, pp. 556-561. https://doi.org/10.1002/cncr.29085
Issa, Jean Pierre ; Garcia-Manero, Guillermo ; Huang, Xuelin ; Cortes, Jorge ; Ravandi, Farhad ; Jabbour, Elias ; Borthakur, Gautam ; Brandt, Mark ; Pierce, Sherry ; Kantarjian, Hagop M. / Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. In: Cancer. 2015 ; Vol. 121, No. 4. pp. 556-561.
@article{010f30f7926f4419abd325227d3abdfd,
title = "Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia",
abstract = "BACKGROUND: Hypomethylating agents have demonstrated activity in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Preclinical and single-arm trials have suggested that adding histone deacetylase (HDAC) inhibitors may synergize the epigenetic modulation of hypomethylating agents and improve treatment results. METHODS: The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML. RESULTS: Patients with higher risk MDS or with AML aged ≥60 years were eligible. Patients were randomized in a Bayesian response-adaptive design to receive intravenous decitabine 20 mg/m2 daily for 5 days or decitabine plus oral valproic acid 50 mg/kg daily for 7 days. Courses were repeated every 4 to 6 weeks. A maximum of 150 patients were to be treated. In total, 149 patients were treated on study, including 87 patients with MDS and 62 patients with AML. The median patient age was 69 years (range, 20-89 years; 42{\%} of patients were aged ≥70 years). Overall, 34{\%} of patients achieved complete remission, and 55{\%} had an objective response. The median survival was 11.9 months, and the estimated 2-year survival rate was 27{\%}. Outcome was not different with the addition of valproic acid to decitabine versus decitabine alone in relation to the rates of complete remission, overall response, or survival. Subset analyses did not demonstrate a benefit within the MDS or AML categories. Toxicities - particularly neurotoxicities - were higher with the combination arm. CONCLUSIONS: Adding valproic acid to decitabine was not associated with improved outcome in the treatment of patients with MDS or elderly patients with AML. Future therapies may consider combining hypomethylating agents with better HDAC inhibitors and using different schedules.",
keywords = "Acute myelogenous leukemia, Decitabine, Histone deacetylase, Hypomethylating agents, Inhibitors, Myelodysplastic syndrome, Trials, Valproic acid",
author = "Issa, {Jean Pierre} and Guillermo Garcia-Manero and Xuelin Huang and Jorge Cortes and Farhad Ravandi and Elias Jabbour and Gautam Borthakur and Mark Brandt and Sherry Pierce and Kantarjian, {Hagop M.}",
year = "2015",
month = "2",
day = "1",
doi = "10.1002/cncr.29085",
language = "English (US)",
volume = "121",
pages = "556--561",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

AU - Issa, Jean Pierre

AU - Garcia-Manero, Guillermo

AU - Huang, Xuelin

AU - Cortes, Jorge

AU - Ravandi, Farhad

AU - Jabbour, Elias

AU - Borthakur, Gautam

AU - Brandt, Mark

AU - Pierce, Sherry

AU - Kantarjian, Hagop M.

PY - 2015/2/1

Y1 - 2015/2/1

N2 - BACKGROUND: Hypomethylating agents have demonstrated activity in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Preclinical and single-arm trials have suggested that adding histone deacetylase (HDAC) inhibitors may synergize the epigenetic modulation of hypomethylating agents and improve treatment results. METHODS: The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML. RESULTS: Patients with higher risk MDS or with AML aged ≥60 years were eligible. Patients were randomized in a Bayesian response-adaptive design to receive intravenous decitabine 20 mg/m2 daily for 5 days or decitabine plus oral valproic acid 50 mg/kg daily for 7 days. Courses were repeated every 4 to 6 weeks. A maximum of 150 patients were to be treated. In total, 149 patients were treated on study, including 87 patients with MDS and 62 patients with AML. The median patient age was 69 years (range, 20-89 years; 42% of patients were aged ≥70 years). Overall, 34% of patients achieved complete remission, and 55% had an objective response. The median survival was 11.9 months, and the estimated 2-year survival rate was 27%. Outcome was not different with the addition of valproic acid to decitabine versus decitabine alone in relation to the rates of complete remission, overall response, or survival. Subset analyses did not demonstrate a benefit within the MDS or AML categories. Toxicities - particularly neurotoxicities - were higher with the combination arm. CONCLUSIONS: Adding valproic acid to decitabine was not associated with improved outcome in the treatment of patients with MDS or elderly patients with AML. Future therapies may consider combining hypomethylating agents with better HDAC inhibitors and using different schedules.

AB - BACKGROUND: Hypomethylating agents have demonstrated activity in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Preclinical and single-arm trials have suggested that adding histone deacetylase (HDAC) inhibitors may synergize the epigenetic modulation of hypomethylating agents and improve treatment results. METHODS: The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML. RESULTS: Patients with higher risk MDS or with AML aged ≥60 years were eligible. Patients were randomized in a Bayesian response-adaptive design to receive intravenous decitabine 20 mg/m2 daily for 5 days or decitabine plus oral valproic acid 50 mg/kg daily for 7 days. Courses were repeated every 4 to 6 weeks. A maximum of 150 patients were to be treated. In total, 149 patients were treated on study, including 87 patients with MDS and 62 patients with AML. The median patient age was 69 years (range, 20-89 years; 42% of patients were aged ≥70 years). Overall, 34% of patients achieved complete remission, and 55% had an objective response. The median survival was 11.9 months, and the estimated 2-year survival rate was 27%. Outcome was not different with the addition of valproic acid to decitabine versus decitabine alone in relation to the rates of complete remission, overall response, or survival. Subset analyses did not demonstrate a benefit within the MDS or AML categories. Toxicities - particularly neurotoxicities - were higher with the combination arm. CONCLUSIONS: Adding valproic acid to decitabine was not associated with improved outcome in the treatment of patients with MDS or elderly patients with AML. Future therapies may consider combining hypomethylating agents with better HDAC inhibitors and using different schedules.

KW - Acute myelogenous leukemia

KW - Decitabine

KW - Histone deacetylase

KW - Hypomethylating agents

KW - Inhibitors

KW - Myelodysplastic syndrome

KW - Trials

KW - Valproic acid

UR - http://www.scopus.com/inward/record.url?scp=84922513553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922513553&partnerID=8YFLogxK

U2 - 10.1002/cncr.29085

DO - 10.1002/cncr.29085

M3 - Article

C2 - 25336333

AN - SCOPUS:84922513553

VL - 121

SP - 556

EP - 561

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -